$Impact of pegloticase on patient outcomes in refractory gout: current perspectives$
Código QR

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

Rita N Cunha,1 Renata Aguiar,1 Filipa Farinha2 1Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal; 2Centre for Rheumatology, University College London, London, UK Abstract: Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cunha RN, Aguiar R, Farinha F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	gout urate- lowering therapy pegloticase patient outcomes Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/0f364a6f388248df917e019a1dfdccbb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f364a6f388248df917e019a1dfdccbb
record_format	dspace
spelling	oai:doaj.org-article:0f364a6f388248df917e019a1dfdccbb2021-12-02T09:14:20ZImpact of pegloticase on patient outcomes in refractory gout: current perspectives1179-156Xhttps://doaj.org/article/0f364a6f388248df917e019a1dfdccbb2018-10-01T00:00:00Zhttps://www.dovepress.com/impact-of-pegloticase-on-patient-outcomes-in-refractory-gout-current-p-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XRita N Cunha,1 Renata Aguiar,1 Filipa Farinha2 1Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal; 2Centre for Rheumatology, University College London, London, UK Abstract: Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This condition is associated with acute flares and, if untreated or refractory, chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering therapy. In this review, we discuss the impact of pegloticase on patient outcomes in refractory gout. We analyze different parameters, such as plasma uric acid concentration, frequency of flares, tophi reduction, pain, function, quality of life, and safety. Keywords: gout, urate-lowering therapy, pegloticase, patient outcomesCunha RNAguiar RFarinha FDove Medical Pressarticlegouturate- lowering therapypegloticasepatient outcomesDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 141-149 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	gout urate- lowering therapy pegloticase patient outcomes Diseases of the musculoskeletal system RC925-935
spellingShingle	gout urate- lowering therapy pegloticase patient outcomes Diseases of the musculoskeletal system RC925-935 Cunha RN Aguiar R Farinha F Impact of pegloticase on patient outcomes in refractory gout: current perspectives
description	Rita N Cunha,1 Renata Aguiar,1 Filipa Farinha2 1Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal; 2Centre for Rheumatology, University College London, London, UK Abstract: Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This condition is associated with acute flares and, if untreated or refractory, chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering therapy. In this review, we discuss the impact of pegloticase on patient outcomes in refractory gout. We analyze different parameters, such as plasma uric acid concentration, frequency of flares, tophi reduction, pain, function, quality of life, and safety. Keywords: gout, urate-lowering therapy, pegloticase, patient outcomes
format	article
author	Cunha RN Aguiar R Farinha F
author_facet	Cunha RN Aguiar R Farinha F
author_sort	Cunha RN
title	Impact of pegloticase on patient outcomes in refractory gout: current perspectives
title_short	Impact of pegloticase on patient outcomes in refractory gout: current perspectives
title_full	Impact of pegloticase on patient outcomes in refractory gout: current perspectives
title_fullStr	Impact of pegloticase on patient outcomes in refractory gout: current perspectives
title_full_unstemmed	Impact of pegloticase on patient outcomes in refractory gout: current perspectives
title_sort	impact of pegloticase on patient outcomes in refractory gout: current perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0f364a6f388248df917e019a1dfdccbb
work_keys_str_mv	AT cunharn impactofpegloticaseonpatientoutcomesinrefractorygoutcurrentperspectives AT aguiarr impactofpegloticaseonpatientoutcomesinrefractorygoutcurrentperspectives AT farinhaf impactofpegloticaseonpatientoutcomesinrefractorygoutcurrentperspectives
_version_	1718398165850259456

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

Ejemplares similares